An Overview on Airborne Transmission

Ayan Raichaudhuri^*
*Correspondence: Ayan Raichaudhuri, Department of Medicine, Saga University, Saga, Japan, Email:

Introduction

Coughs and sneezes, spraying liquid, and dust are all ways for airborne infections to spread. Microorganisms can come from a sick person or animal, as well as soil, rubbish, and other places. There are numerous forms of airborne diseases, each with its own set of symptoms, treatment, and prognosis. Personal protective clothing and appropriate ventilation systems are two ways to prevent transmission. Individuals can help prevent illness transmission by avoiding direct contact with others or wearing a facial covering, depending on the ailment. Depending on the germ involved, airborne infections can spread via direct or indirect transmission, according to the Centers for Disease Control and Prevention (CDC) Trusted Source. When someone breathes or sneezes, germs can enter the air in the form of wet droplets. They'll float in the air, and some of the droplets will dry out, leaving minute particles. These particles can cling to or enter the bodies of persons nearby while suspended in the air.

Description

The spread of an infectious disease through microscopic particles dispersed in the air is known as airborne or aerosol transmission. Infectious diseases that can be transmitted through the air include a wide range of diseases that are important in both human and veterinary medicine. Viruses, bacteria, and fungus are examples of infectious agents that can be disseminated through breathing, talking, coughing, sneezing, raising dust, spraying liquids, flushing toilets, or any other activity that produces aerosol particles or droplets. This refers to disease transmission by the spread of an infectious agent and excludes diseases induced by air pollution. Airborne transmission has long been thought to be separate from droplet transmission, although this is erroneous. After ejection, respiratory droplets were assumed to fall quickly to the ground.

Aerosols and droplets come in a variety of sizes and concentrations, and the amount produced varies greatly depending on the person and activity. Droplets larger than 100 m in diameter usually settle within 2 m, airborne diseases can be carried for longer periods of time by smaller particles. While airborne infections have a higher concentration within 2 metres, they can move further and concentrate in a room. Some particles, such as the fungus Aspergillus, are found in large quantities in the environment Trusted Source. It can be found in soil, plants, and food and water, as well as decomposing plant waste, home dust, and building materials. Breathing in dust containing the fungus during construction may cause sickness in certain persons.

Exhaled particles constitute a continuum of sizes whose fates are dependent on environmental factors in addition to their original sizes, therefore the traditional size cut-off of 5 m between airborne and respiratory droplets has been abandoned. For decades, this inaccuracy has informed hospital-based transmission-based measures. According to data from indoor respiratory secretion transfer, droplets/aerosols in the 20 m size range travel with the air flow from cough jets and air conditioning like aerosols, but then fall out gravitationally at a greater distance as "jet riders." Because aerosols/ droplets in this size range are most efficiently filtered out in the nasal mucosa, the primary infection site in COVID-19, they may play a role in fueling the COVID-19 pandemic [1].

Diseases that are spread through the air might be passed from one person to the next. Pathogens can be any type of germ and can be disseminated through aerosols, dust, or drops. The aerosols could come from sources of infection, such as an infected person's bodily secretions or biological waste. Infectious aerosols can float in air currents for long periods of time, allowing them to travel large distances; sneezes, for example, can readily project infectious droplets for dozens of feet (ten or more meters). Pathogens or allergens inhaled through the air enter the body through the nose, throat, sinuses, and lungs. When these pathogens are inhaled, they harm the respiratory system, which can subsequently spread to the rest of the body. Inflammation in the upper respiratory airway can cause sinus congestion, coughing, and sore throats. Air pollution is a major contributor to airborne infections. Pollutants can affect lung function by causing inflammation in the airways [2,3].

COVID-19, measles morbillivirus, chickenpox virus, Mycobacterium tuberculosis, influenza virus, enterovirus, norovirus, and less commonly coronavirus, adenovirus, and perhaps respiratory syncytial virus are all prevalent illnesses spread by airborne transmission. Poor ventilation aids transmission by allowing aerosols to move unhindered in an enclosed environment. Infected people are more likely to be found in crowded rooms. The longer a vulnerable person remains in such an environment, the greater the risk of transmission. Although airborne transmission is difficult to prove clearly, the Wells-Riley model can be utilised to create simple infection probability estimations [4,5].

Conclusion

Disease-specific vaccine, wearing a respirator, and limiting time spent in the vicinity of infected individuals are all preventative measures. Because it slows the air movement between people, wearing a face mask can reduce the likelihood of transmission. The size of the particles determines the type of mask that is effective against airborne transmission; while fluid-resistant surgical masks prevent droplet inhalation; smaller particles that form aerosols require a higher level of protection, requiring filtration masks rated at N95 (US) or FFP3 (EU). The use of FFP3 masks by workers caring for COVID-19 patients reduced COVID-19 acquisition by staff. Personal protective equipment (PPE) is at the bottom of the control hierarchy, behind engineering solutions that try to reduce or eliminate exposure.

References

1. Allie, Nasiema, Sergei I. Grivennikov, Roanne Keeton and Nai-Jen Hsu et al. "Prominent role for T cell-derived tumour necrosis factor for sustained control of Mycobacterium tuberculosis infection."    Sci. Rep. 3 (2013): 1-14.

Indexed at, Crossref, Google Scholar

2. Amiri-Kordestani, Laleh, Gideon M. Blumenthal, Qiang Casey Xu and Lijun Zhang  et al. "FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer." Clin. Cancer Res. 20 (2014): 4436-4441.

Indexed at, Crossref, Google Scholar

3. Amoury, Manal, Katharina Kolberg, Anh-Tuan Pham, Dmitrij Hristodorov and  Radoslav Mladenov et al. "Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model." Cancer Lett. 372 (2016): 201-209.

Indexed at, Crossref, Google Scholar

4. Anderson, Ana C., Nicole Joller, and Vijay K. Kuchroo. "Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation." Immunity 44 (2016): 989-1004.

Indexed at, Crossref, Google Scholar

5. Araki, Koichi, Ben Youngblood, and Rafi Ahmed. "Programmed cell death 1-directed immunotherapy for enhancing T-cell function." Cold Spring Harb. Symp. Quant. Biol. 78(2013): 239-247.

Indexed at, Crossref, Google Scholar